Trial Profile
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2022
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma
- Focus Therapeutic Use
- 07 Aug 2021 Status changed from active, no longer recruiting to completed.
- 27 Sep 2019 Planned End Date changed from 1 Sep 2020 to 1 Sep 2021.
- 27 Sep 2019 Planned primary completion date changed from 1 Sep 2020 to 1 Sep 2021.